ATRC
Atricure Inc

392
Loading...
Loading...
News
all
press releases
AtriCure (ATRC) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for AtriCure (ATRC) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Zacks·1mo ago
News Placeholder
More News
News Placeholder
AtriCure (ATRC) Reports Q2 Loss, Tops Revenue Estimates
AtriCure (ATRC) delivered earnings and revenue surprises of +86.67% and +4.61%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
Abbott (ABT) Q2 Earnings and Revenues Top Estimates
Abbott (ABT) delivered earnings and revenue surprises of +0.80% and +0.63%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·2mo ago
News Placeholder
Has Amneal Pharmaceuticals (AMRX) Outpaced Other Medical Stocks This Year?
Here is how Amneal Pharmaceuticals (AMRX) and AtriCure (ATRC) have performed compared to their sector so far this year.
Zacks·2mo ago
News Placeholder
Are Medical Stocks Lagging Astellas Pharma (ALPMY) This Year?
Zacks·3mo ago
News Placeholder
Is Astellas Pharma (ALPMY) Stock Outpacing Its Medical Peers This Year?
Zacks·4mo ago
News Placeholder
Does AtriCure (ATRC) Have the Potential to Rally 54.7% as Wall Street Analysts Expect?
Zacks·4mo ago
News Placeholder
Why Barclays sees a buying opportuntiy in MedTech stocks
Investing.com -- Barclays said in a note Monday that it sees attractive entry points in MedTech stocks, as recent weakness in some sector leaders has created a buying opportunity despite the group’s strong year-to-date performance.
investing.com·6mo ago
News Placeholder
AtriCure Reports Fourth Quarter 2024 and Full Year 2024 Financial Results
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management...
Business Wire·7mo ago
News Placeholder
AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2024, Provides Financial Outlook for 2025, and Announces Upcoming Analyst and Investor Day
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management...
Business Wire·8mo ago

Latest ATRC News

View

Advertisement. Remove ads.

Advertisement. Remove ads.